Product Breakthroughs Bimeda's recent product launches demonstrate a strong cross-species portfolio, including BOVitalize Plus enhanced with Aspergillus oryzae for cattle health and digestion, and GASTROBIM (omeprazole), the first FDA-approved bioequivalent for equine gastric ulcers. This enables targeted sales in cattle, equine clinics, and large animal feedlots, with regulatory-backed claims supporting premium positioning.

US Market Growth A series of new U.S. hires — a Swine Technical Service Veterinarian, a Director of US Technical Services, and a Territory Manager — signals expanded field coverage and technical support. This strengthens consultative selling, helps speed product adoption, and opens doors in swine, cattle, and equine customer segments.

Distributor Alliances Strategic partnerships with distributors in Ireland and the UK, along with ongoing export partnerships, position Bimeda to scale through multi-market channels. This offers opportunities for coordinated launches, bundled offerings, and cross-border supply to large veterinary practices and integrators.

Regulatory Edge ISO 13485 certification and FDA-equivalent product approvals bolster credibility with clinics and specialty practices that demand high-quality, compliant suppliers. Use this advantage to win contracts with premium distributors and hospital-grade animal health buyers.

Multi-Species Growth A diverse portfolio spanning cattle digestion aids, equine gastric ulcer treatment, and swine technical services enables cross-selling within mixed-animal practices and veterinary groups. Leverage partnerships and field staff to propose bundled, multi-species solutions and expand share of wallet.